Abrogation of FGFR signaling blocks β-catenin–induced adrenocortical hyperplasia and aldosterone production
JCI Insight · 10.11.2025 · 10 (21)
DOI: 10.1172/jci.insight.184863 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 16.09.2025. Verfasst von Vasileios Chortis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: beta Catenin, Aldosterone, Receptor, Fibroblast Growth Factor, Type 2, Adrenal Cortex. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, American Heart Association, National Institutes of Health.
Abstract (Originalsprache)
Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors critical for organogenesis and tissue maintenance, including in the adrenal gland. Here we delineate the role of FGFR2 in the morphogenesis, maintenance, and function of the adrenal cortex with a focus on the zona glomerulosa (zG). zG-specific Fgfr2 deletion (Fgfr2-cKO) resulted in impaired zG cell identity, proliferation, and transdifferentiation into zona fasciculata (zF) cells during postnatal development. In adult mice, induced deletion of Fgfr2 led to loss of mature zG cell identity, highlighting the importance of FGFR2 for the maintenance of a differentiated zG state. Strikingly, Fgfr2-cKO was sufficient to fully abrogate β-catenin–induced zG hyperplasia and to reduce aldosterone levels. Finally, short-term treatment with pan-FGFR small molecule inhibitors suppressed aldosterone production in both WT and β-catenin gain-of-function mice. These results demonstrate a critical role for FGFR signaling in adrenal morphogenesis, maintenance, and function and suggest that targeting FGFR signaling may benefit patients with aldosterone excess and/or adrenal hyperplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
- Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Förderung
- NIDDK NIH HHS
- American Heart Association
- National Institutes of Health
Zitieren
APA
Chortis, V., Kariyawasam, D., Berber, M., Guagliardo, N. A., Leng, S., Haykir, B., Ribeiro, C., Shah, M. S., Pignatti, E., Jorgensen, B., Gaston, L., Barrett, P. Q., Carlone, D. L., Borges, K. S., & Breault, D. T. (2025). Abrogation of FGFR signaling blocks β-catenin–induced adrenocortical hyperplasia and aldosterone production. JCI Insight, 10(21). https://doi.org/10.1172/jci.insight.184863
Vancouver
Chortis V, Kariyawasam D, Berber M, Guagliardo NA, Leng S, Haykir B, et al. Abrogation of FGFR signaling blocks β-catenin–induced adrenocortical hyperplasia and aldosterone production. JCI Insight. 2025;10(21). doi:10.1172/jci.insight.184863
BibTeX
@article{Chortis2025,
author = {Chortis, Vasileios and Kariyawasam, Dulanjalee and Berber, Mesut and Guagliardo, Nick A and Leng, Sining and Haykir, Betul and Ribeiro, Claudio and Shah, Manasvi S and Pignatti, Emanuele and Jorgensen, Brenna and Gaston, Lindsey and Barrett, Paula Q and Carlone, Diana L and Borges, Kleiton Silva and Breault, David T},
title = {Abrogation of FGFR signaling blocks β-catenin–induced adrenocortical hyperplasia and aldosterone production},
journal = {JCI Insight},
year = {2025},
volume = {10},
number = {21},
doi = {10.1172/jci.insight.184863}
}
EUVIMED